injection drug user

BNET Resources

• sort by:
• Relevance
• Date
• Popularity

Reducing Sexual Risk Among Injection Drug Users

Multiple sexual partnerships, sex work, and unprotected intercourse are common among injection drug users IDUs. IDUs are also more likely to engage in heterosexual anal intercourse, which is associated with greater risk for HIV transmission than is vaginal sex. Thus, reducing IDUs' sexual risk is an important step in stemming...

Tags: Risk, Ingersoll-Rand, HIV Virus, Injection Drug User, Strategy, Security, Management

White papers 2005-01-14

Additional Resources

Alkermes Announces Priority Review Granted for Vivitrex -Naltrexone Long-Acting Injection- NDA Submission

CAMBRIDGE, Mass. -- Alkermes, Inc. (Nasdaq: ALKS) today announced that the New Drug Application ("NDA") for VivitrexR (naltrexone long-acting injection) has been accepted for review by the United States Food and Drug Administration ("FDA") and has been granted a Priority Review designation. The Prescription Drug User Fee Act ("PDUFA") date...

Tags: FDA, injection

Research articles 2005-05-27

HHS Extends Use of Rapid Oral HIV Test to New Sites Nationwide; Will Fund Use of Rapid Test For Injection Drug User Community

WASHINGTON, June 25 /U.S. Newswire/ -- HHS Secretary Tommy G. Thompson today announced that HHS has extended the availability of a recently approved rapid oral HIV test from the current 38,000 laboratories permitted to perform the test to more than 100,00WASHINGTON, June 25 /U.S. Newswire/ -- HHS Secretary Tommy G....

Tags: U.S. Department of Health and Human Services

Research articles 2004-06-25

FDA Extends PDUFA Date for VIVITREX® to December 30, 2005; Cephalon and Alkermes Continue to Anticipate VIVITREX Launch in First Half of 2006

FRAZER, Pa. & CAMBRIDGE, Mass. -- Cephalon, Inc. (Nasdaq: CEPH) and Alkermes, Inc. (Nasdaq: ALKS) announced today that they have received notification from the United States Food and Drug Administration FDA that the agency has extended the action date to December 30, 2005 for its priority review of the New...

Tags: Cephalon Inc., FDA

Research articles 2005-09-20

Dacogen™ Injection Complete Response Accepted for Review By U.S. FDA

MINNEAPOLIS & DUBLIN, Calif. -- MGI PHARMA, INC. (Nasdaq:MOGN) and SuperGen, Inc. (Nasdaq:SUPG) today announced that the U.S. Food and Drug Administration FDA has accepted the Companies' resubmission as of November 15, 2005 as a complete response to the Approvable Letter for DacogenTM decitabine injection for myelodysplastic syndromes MDS. The...

Tags: FDA

Research articles 2005-12-15